pharmaceutical-investing Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
pharmaceutical-investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
pharmaceutical-investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
pharmaceutical-investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
pharmaceutical-investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Yorkville America Equities and Truth Social ETFs Announce Proposed Acquisition of the God Bless America ETF
JPMorganChase to Match U.S. Government's $1,000 Contribution to Trump Accounts for Employees' Children
